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Abstract
Background: Head and neck cancer squamous cell carcinoma (HNSSC) patients report substantial rates of clinically
significant depression and/or anxiety, with dysphagia being a predictor of distress and poorer quality of life.
Evidence-based dysphagia interventions largely focus on the remediation of physical impairment. This feasibility
study evaluates an intervention which simultaneously uses a psychological therapy approach combined with
swallowing impairment rehabilitation.
Methods: This prospective single cohort mixed-methods study, recruited HNSCC patients with dysphagia, from two
institutions. The intervention combined Cognitive Behavioural Therapy with swallowing therapy (CB-EST), was
individually tailored, for up to 10 sessions and delivered by a speech and language therapist. Primary acceptability
and feasibility measures included recruitment and retention rates, data completion, intervention fidelity and the
responsiveness of candidate outcome measures. Measures included a swallowing questionnaire (MDADI), EORTC-
QLQH&N35, dietary restrictions scale, fatigue and function scales and the Hospital Anxiety and Depression Scale
(HADS), administered pre-, post-CB-EST with three month follow-up and analysed using repeated measures ANOVA.
Qualitative interviews were conducted to evaluate intervention processes.
Results: A total of 30/43 (70%) eligible patients agreed to participate and 25 completed the intervention. 84% were
male, mean age 59 yrs. Patients were between 1 and 60 months (median 4) post-cancer treatment. All patients had
advanced stage disease, treated with surgery and radiotherapy (38%) or primary chemoradiotherapy (62%). Pre to
post CB-EST data showed improvements in MDADI scores (p = 0.002), EORTC-QLQH&N35 (p = 0.006), dietary scale
(p < 0.0001), fatigue (p = 0.002) but no change in function scales or HADS. Barriers to recruitment were the ability to
attend regular appointments and patient suitability or openness to a psychological-based intervention.
Conclusions: CB-EST is a complex and novel intervention, addressing the emotional, behavioural and cognitive
components of dysphagia alongside physical impairment. Preliminary results are promising. Further research is
required to evaluate efficacy and effectiveness.
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Background
Chronic swallowing difficulties (dysphagia) are a com-
mon and highly distressing side effect of surgery and/or
(chemo)radiotherapy for the treatment of head and neck
cancer (HNSCC) [1]. Dysphagia is associated with a
higher risk of pneumonia, poor oral intake, malnutrition
and prolonged tube feeding [2]. HNSSC patients report
substantial rates of clinically significant depression and/
or anxiety, with dysphagia being a predictor of distress
[3, 4]. Our previous qualitative work reported on funda-
mental changes to eating habits, social lives and well-
being, with some patients being better able to adjust to
such changes than others [5].
Evidence based HNSCC dysphagia interventions largely
centre on impairment-focused treatments delivered by
speech & language therapists (SLTs) [6]. These typically in-
clude exercises to increase the range and co-ordination of
swallowing function, to improve efficiency and safety. These
may be administered before (as a preventative approach),
during or after HNSCC treatment. The degree to which ex-
ercises prevent or reduce dysphagia is unclear due to poor
patient adherence and differing exercise protocols [7]. Pa-
tients need support in coping with side effects [8], but to
date, there are minimal reports of interventions addressing
the psychosocial sequelae of dysphagia.
General psychosocial interventions for HNSCC patients
such as psycho-education, counselling and cognitive be-
havioural therapy (CBT) have been reported. A Cochrane
review concluded that the subsequent impact on quality
of life of these interventions was uncertain due to study
design limitations [9]. Whether a psychological-based
treatment can be combined with impairment-based swal-
lowing therapy to address dysphagia is an unknown.
Potentially this type of intervention could improve patient
engagement with rehabilitation and facilitate adjustment
in living with swallowing difficulties. CBT has previously
been used with HNSCC [10] and has been used by SLTs
for other conditions [11].
This study aims to investigate the feasibility and
acceptability of a cognitive behavioural enhanced
swallowing therapy (CB-EST) for HNSCC dysphagia,
using a mixed methods design.
Methods
This is a multi-centre, prospective, longitudinal non-
randomised single cohort study to explore feasibility and
acceptability of a CBT enhanced swallowing therapy
intervention (CB-EST) in HNSCC patients. The feasibil-
ity design was informed by guidance set out by the
CONSORT 2010 statement [12].
Patients and eligibility
HNSCC patients were recruited from two units in NE
England. They were eligible for the study if they 1) had
completed HNSCC treatment with curative intent 2)
were medically stable and 3) scored <80 points on the
MD Anderson Dysphagia Inventory [13] (swallowing
specific quality of life questionnaire). Patients were ex-
cluded if they 1) had pre-existing major psychiatric diag-
nosis 2) had residual/recurrent HNSCC 3) were on a
palliative care pathway 4) had significant communication
difficulties rendering them unable to participate in a
talking therapy 5) were currently receiving a psycho-
logical intervention 6) were awaiting an intervention for
the purpose of improving swallowing performance (e.g. a
dilatation) or 7) had significant ill-health precluding
regular hospital attendance. Patients were screened and
approached by members of the multi-disciplinary
HNSCCC team and gave written consent before partici-
pation. The study aimed to recruit thirty participants, to
provide data to perform a sample size calculation for a
potential future effectiveness study [14].
Intervention
The main researcher (JP), a SLT trained in CBT to post
graduate certificate level, delivered the intervention. CB-
EST was individually tailored, but aimed to include key
CBT components i.e. in-depth assessment, identification
of maintaining factors within a formulation, identifica-
tion of a therapy goal, Socratic questioning style, cogni-
tive and/or behavioural therapy techniques and
homework tasks. The intervention also included indivi-
dualised swallowing exercises, diet modifications and
food texture advice, if appropriate to the patient’s ther-
apy goal. Between 45 and 60 min were allowed for each
session. Treatment was on a weekly or fortnightly basis
(depending on patient preference and need for support)
for up to 10 sessions by mutual agreement, with a follow
up assessment at three months to monitor generalisation
and maintenance. JP received supervision from an expert
CBT practitioner every 2–3 weeks.
Feasibility outcomes
As this was primarily a feasibility study, primary out-
comes were those that related to the acceptability of the
intervention to participants and the feasibility of trialling
the intervention in a larger study. The acceptability and
feasibility outcomes are as follows:
1. Acceptability was measured by the proportion of
patients approached and consented and the number
of sessions attended. Retention rates and reasons for
drop out was documented. We aimed for a 50%
recruitment rate for CB-EST to be deemed an ac-
ceptable treatment.
2. Feasibility and fidelity were measured by assessing
whether the intervention could be delivered as
planned, by a SLT with CBT training. Session
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content and treatment plans, recorded in patients’
notes were evaluated by a CBT expert practitioner
as part of supervision, reliability and validity
checking. Content analysis of sessions including a)
whether a therapy goal was identified b) whether a
CBT formulation was identified c) whether cognitive
and/or behaviour change techniques were used.
These outcomes would also indicate the
acceptability of the intervention to patients.
3. A selection of candidate measures targeting
swallowing self-report, dietary restrictions, quality of
life, functioning and mood were chosen to identify
appropriate tools to capture CB-EST outcomes. Ac-
ceptability to patients was monitored by percentage
data completion. The measures listed below and
were administered pre-, immediately following CB-
EST, and at three months.
i. The MDADI [13] has twenty items, each marked
using a five-point scale and summarised using a total
score (range 20–100). Higher scores indicate a better
outcome and a change in ≥10 points is considered a
clinically significant difference [15].
ii. The European Organization for Research and
Treatment of Cancer questionnaires (EORTC
QLQ-C30) [16] is a general quality of life
questionnaire with 30 items, five functioning scales
(physical, role, emotional, cognitive, and social), three
symptom scales. The EORTC QLQ-H&N35 is a
disease-specific module of 35 questions divided into 7
subscales about pain, swallowing, senses, speech, so-
cial eating, social contact, and sexuality. Higher scores
on the functional scales refer to better health status,
whereas higher scores in symptom scales and the
QLQ-H&N35 represent more severe symptoms.
iii. Chalder Fatigue Questionnaire (CFQ-11) [17]
measures fatigue severity. Eleven items are answered
on a four-point scale (range 0–33), with high scores
representing more fatigue.
iv. Work and Social Adjustment Scale(WASA) [18]
measures functional and social impairment. Five
questions are answered on a nine-point scale (range
0–40) with higher scores indicating more impairment.
v. Hospital Anxiety and Depression Scale (HADS)
[19] has two seven item subscales measuring
anxiety (HADS-A) and depression (HADS-D).
Each item is scored on a four-point scale (range
0–21 for each subscale). Subscale scores 0–7
classify participants as non-cases, 8–10 indicates
borderline cases, and scores ≥11 indicate clinical
levels. Total HADS scores (HADS-T) ≥ 15 indicate
clinically significant distress.
vi. Performance Status Scales (PSS) Normalcy of Diet
[20] measures diet texture restrictions and is
clinician-rated. The scale has ten ranked categories
ranging from 0 (nil by mouth) to 100 (full diet
without restrictions).
The presence of a feeding tube was recorded at the
same time points. The sensitivity of the candidate mea-
sures was tested by making preliminary estimates of
change from pre- to post CB-EST. Data were analysed
using SPSS v21 (Chicago, Illinois). We used a one way
within subjects repeated measures analysis of variance
complete case model. The level for statistical significance
was set at 0.05. Bonferroni’s test was used for multiple
post hoc comparisons. Means are reported with standard
deviations and 95% confidence intervals.
4. The acceptability and feasibility of delivering
CB-EST as-was or modifying it for a larger trial was
further assessed using semi-structured interviews.
Patients were purposively sampled to ensure a range
of pre to post CB-EST changes in MDADI scores, a
range of HNSCC treatment and time post-
treatment. Patients were selected from those at the
initial stages of CB-EST and at the end of CB-EST.
Interviews were conducted by two independent
researchers. Patients had the option of a telephone
or face to face interview, at a time and place of their
choice. All interviews were digitally recorded, t
ranscribed verbatim and anonymised. Transcripts
were read several times and in detail by the qualita-
tive sub-team. Data were then discussed and coded
using thematic analysis. Quotations relating to afore
mentioned topics were independently selected and
coded into key issues and themes.
Ethics
Ethical approval was granted by the UK North East
Research Ethics Committee reference 14/NE/1045.
Results
Feasibility and acceptability as measured by recruitment
and retention
Fifty patients were screened over 20 months. Seven
patients reported that their eating and drinking issues
had resolved and/or they scored >80 on the MDADI, so
were ineligible. Forty-three patients were approached
and 30 gave written consent (69.8%). Patient characteris-
tics for consented patients are summarised in Table 1.
There was no statistical difference in distribution of gen-
der, age, disease site, stage, type of treatment or time
since treatment (p > 0.05) between those that consented
to participation and those that did not.
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Reasons for non-participation included difficulties
with regular hospital attendance (5), did not think
CB-EST would help (3), did not attend (2), currently
receiving CBT (1), and too much to take on (2).
Twenty five patients were retained (83%) in the inter-
vention. Three patients dropped out at sessions 3, 4
and 5 due to disease (2 local disease, 1 lung cancer).
Two patients opted not to continue with CB-EST at
session 2 and 5; one found it difficult to envisage
how CB-EST might be of benefit and the other felt
he was making insufficient progress. No outcome data
were available for drop-outs. The number of CB-EST
sessions for the retained patients ranged from 3 to 10
sessions, median 6. At three month follow up, one
patient was too unwell to complete questionnaires.
Feasibility and acceptability as measured by intervention
fidelity
All retained patients were able to identify a goal specific to
their eating and drinking problem. Goals fell into six main
areas (see Table 2). A formulation for all but one drop-out
patient was developed and verified during supervision. Ex-
amples of formulations are provided in Fig. 1. A range of
cognitive and behavioural techniques were utilised during
CB-EST and are recorded in Table 2.
Acceptability and utility of candidate outcome measures
Data completeness ranged from 76 to 100%, the PSS
Normalcy of diet scale having the highest compliance,
QLQ-C30 having the lowest compliance (see Table 3).
Post CB-EST improvements were observed in several
measures. Although not powered for effectiveness, a sta-
tistically significant improvement was observed in
MDADI scores (p = 0.002, mean difference 8.1); three
domains of QLQ-C30 function scales (p = 0.004–0.03
mean difference 10.4–21.3); seven domains on QLQ-
HN35 symptoms scales (p < 0.0001–0.01 mean differ-
ence 10.8–14.7); CFS (p = 0.002 mean difference 4.1) and
PSS Normalcy of diet scale (p < 0.0001 mean difference
15.8). These improvements were maintained at three
months. No statistical improvement was observed for
two domains on QLQ-C30 functioning scales; two
domains on QLQ-HN35 symptom scales; WASA scales
or the HADS (see Table 3).
Feasibility and acceptability as measured by participant
interviews
Sixteen patients were approached for interview and 15
consented. The interviewer was unable to arrange a
convenient time for three patients. There were ten
telephone and two face to face interviews. One patient
opted to be interviewed with her partner present. The
sample reflected baseline characteristics for gender, age,
site and stage of disease (see Table 4).
Three main CB-EST process themes were identified.
Duration and frequency
Participants were referred to CB-EST either by a special-
ist nurse or a SLT and all felt this was an appropriate
pathway. Overall, patients were happy with the duration
of sessions. Session length of approximately one hour
was deemed sufficient to explore issues and to decide on
homework until the following session. Generally,
patients felt that between 8 and 10 sessions was an ap-
propriate set of meetings. Some felt that regular intervals
(weekly/fortnightly) were beneficial whilst others would
have preferred them to be more frequent in the early
stages of CB-EST.
Table 1 Patient baseline characteristics and demographics for
consented CB-EST patients
Characteristics Number (%)
Gender
Male 26 (87)
Female 4 (13)
Age 59 (range 49–79)
Disease site
Oropharynx 18 (60)
Oral 5 (17)
Nasopharynx 3 (10)
Larynx 2 (7)
Hypopharynx 1 (3)
Unknown primary 1 (3)
Stage
0 1 (3)
1 2 (6)
2 13 (43)
3 7 (24)
4 7 (24)
Nodes
0 3 (10)
1 7 (24)
2 20 (66)
Treatment
Chemoradiotherapy 19 (63)
Surgery and radiotherapy
+/− chemotherapy
9 (30)
Surgery 1 (3.5)
Radiotherapy 1 (3.5)
Time post-treatment (months) Median 4 (IQR, Range 3,13; 1–60)
Partner Yes (23)
No (7)
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‘The timeframe between that was just balanced nicely
and allowed me to kind of make those plans and have
an experience to then come back and talk about it, so
yeah it worked well’ (S3 aged 51 yrs).
Participants understood that sessions were a finite
resource and moving on was an inevitable and neces-
sary part of the intervention. Several participants
stated that they would have happily continued as they
discovered an overall benefit on recovery and well--
being. Patients liked the combination of talking,
visualising issues using a whiteboard and other
applied techniques, and concrete goal setting.
Timing
Most participants felt that the timing of their participa-
tion in CB-EST worked well, with some expressing that
they wished they had earlier access.
‘Maybe it should be part of the initial journey and
treatment … not everybody might take it but at least it
is there isn’t it’ (S7 aged 61 years).
There was variation about whether there is an ideal
time point to start sessions. Timing seemed to be re-
lated to individual preferences and symptom severity.
Participants seem to fall roughly into two groups:
those who would prefer the sessions to accompany
their treatment (i.e. start soon after diagnosis) and
those who thought sessions are more beneficial fol-
lowing (but not too long after) treatment.
Suitability
Some participants described themselves as being suited
to an intervention such as CB-EST, i.e. either being open
to talk about emotions and/or relatively open to help
and change. Others described themselves as being more
Fig. 1 Examples of formulations from therapy goals described in Table 2
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reluctant, not used to discussing emotional issues, and
not the type to require psychological support.
‘It will not fit everybody. Some people probably won’t
want to sit there and say about their life and say how
your wife was in tears and say how you were in tears
and talk about things like that‘(S10 aged 54 years).
However, even those unaccustomed to this approach
felt techniques and tasks were tailored to their
requirements. In part, due to the ability to tailor the
intervention, all participants agreed that there is po-
tential for anyone to benefit from CB-EST. Some said
that they didn’t know what to expect but either
approached sessions with an open mind or simply a
‘nothing to lose’ attitude. Even those who thought
they were less likely to get much out of the sessions
reported benefit in interviews, which was not always
reflected in their MDADI scores.
Discussion
CB-EST is a novel treatment and had good rates of pa-
tient uptake and retention; formulations and goals were
possible for most, candidate measures had good uptake
and completeness providing some evidence of effect, and
patients reported that they liked the intervention. CB-
EST was delivered by a CBT trained SLT and was com-
pleted within ten sessions. Results need to be interpreted
with caution as patients were self-selecting and not con-
secutively screened and therefore it is likely that more
willing patients volunteered for the intervention. Re-
cruitment rates were marginally lower than those re-
ported in other general HNSCC psychosocial
interventions [10]. Early indications are that CB-EST is
an acceptable intervention for a range of HNSCC pa-
tients not confined to treatment type, time post-
treatment, or site of disease. The sample was weighted
towards patients with advanced staged disease, the ma-
jority having combined modality treatment. This was
likely due to the predominance of self-reported dyspha-
gia by patients treated with chemoradiotherapy or sur-
gery plus adjuvant radiotherapy [1, 21]. Interview data
suggest that people had individual preferences as to how
soon CB-EST might be offered following their treatment.
Barriers to recruitment were identified. Practicalities of
regular out-patient attendance needs to be taken into
consideration following intensive HNSCC treatment reg-
imens as well as additional financial costs to the patient
[22]. Not all HNSCC patients wish to receive psycho-
logical support and may be unsuitable for such an inter-
vention [23]. Drop-out rates due to disease or ill-health
are expected but unavoidable in the HNSCC population.
Our previous qualitative work showed that patients
view their eating and drinking problems more broadly
than just physical impairment [5]. CB-EST was able to
respond to individual need, addressing the psychosocial
issues of dysphagia by integrating core features of CBT
alongside swallowing therapy, with some reporting
general improvement in their quality of life. The most
common patient goal was removal of feeding tube,
which involved a range of physical, cognitive and
behavioural techniques. Addressing unhelpful thinking
habits was a technique used across all goals. Goals for
improving confidence in social eating or adjustment to
permanent non-oral feeding did not require impairment
based swallowing therapy.
This study employed a selection of candidate measures
to assess patient acceptability and sensitivity to change.
All achieved a completion rate of ≥88%. Outcomes spe-
cifically related to eating and drinking (MDADI, EORTC
HN35 Swallow and Social Eating and PSS Diet score)
were responsive to change, although lack of follow up
data from drop outs may positively skew results.
Elsewhere, a comparable longitudinal cohort study re-
ported a MDADI mean difference of 4.7 points in the
first year post-treatment [24], suggesting some spontan-
eous adjustment occurs. Under trial conditions for a
Table 4 Characteristics of interview participants
Gender
Male 9
Female 3
Age 61 (range 49–70)
Disease site
Oropharynx 8
Oral 1
Nasopharynx 2
Larynx 1
T Stage
2 5
3 5
4 2
Node stage
0 2
1 3
2 7
Treatment
Chemoradiotherapy 9
Surgery and radiotherapy +/− chemotherapy 3
Time post-treatment (months) Median 5 range 1–60
MDADI pre to post CB-EST
Decreased (4–19 points) 3
Similar (0–4 points) 3
Increased (5–36 points) 6
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prophylactic swallow exercise intervention, minimal
change was seen in EORTC HN35 Swallow and Social
Eating scores (mean difference 0 and 5) [25]. The
current study found no change on the HADS, despite
CBT being an effective intervention for anxiety and de-
pression. This may be due to the sample size, although
approximately two thirds of pre-CB-EST patients were
either non-cases or had borderline mood issues accord-
ing to cut-off criteria.
Future work
This preliminary study directs several areas for further
investigation. Future work on refining the selection cri-
teria is required, with early results suggesting that some
patients may be more suitable for CB-EST than others.
CB-EST was delivered by a single SLT; whether SLTs are
willing to be trained, the extent of training and access to
regular supervision is unknown. In order to assess effect-
iveness, CB-EST would need to be protocoled, while
allowing for an individually tailored approach, with fidel-
ity checks. A proportion of patients declined participa-
tion, citing difficulties with regular attendance. It is
uncertain as to whether CB-EST requires face to face
intervention or if components could be administered via
other mediums such as telemedicine, self-help booklets
or web-based programmes. However, patients often ex-
press a preference for individual, face to face help, pref-
erably at home [23]. It is unknown as to whether
patients would be willing to be randomised in the con-
text of a trial. Using MDADI scores, a sample size for a
future trial would require 84 patients, providing 80%
probability of detecting a difference at two sided signifi-
cance level of 0.05. Accounting for an intervention com-
pletion rate of 58% from the available sample, 145
patients would be required to conduct such a study.
Conclusion
The addition of cognitive behavioural techniques to
swallowing therapy delivered by a trained SLT, is a feas-
ible and acceptable treatment, addressing the physical
and psychosocial components of HNSCC dysphagia.
Further work is needed to establish efficacy, effectiveness
and cost-effectiveness of the intervention, in the context
of a randomised controlled trial.
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